Venous thromboembolism (VTE) is a common complication among patients with cancer. The 6-month risk of VTE complication for cancer patients is 12-fold higher and as much as 23-fold higher in those receiving chemotherapy or targeted therapy when compared to patients without cancer [1]. Furthermore, the 12-month cumulative incidence for VTE has increased three-fold over the past two decades in this patient population [1]. Hence, cancer-associated thrombosis (CAT) is a frequent complication that most clinicians caring for patients with cancer must routinely manage.